A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors.
A phase II pediatric trial of a continuous intravenous infusion of 6-mercaptopurine (6-MP) in patients with refractory solid tumors or lymphoma was performed. The dosing schedule of 50 mg/m2 per hour for 48 h was chosen to produce optimal cytotoxic concentrations of 6-MP. There were no complete or partial responses in the 40 patients entered in the trial. Accrual was sufficient for the conclusion to be drawn that there was greater than 95% probability that the true response rate was no greater than 22% and 26% in osteosarcoma and Ewing's sarcoma, respectively. Dose-limiting toxicity was observed in one-third of the patients and included reversible hepatotoxicity, myelosuppression, and mucositis. The excellent penetration of drug into the cerebrospinal fluid (CSF) suggests that future trials of this intravenous dosing schedule should be conducted on tumors of the CNS.
Pediatric Branch, National Cancer Institute, Bethesda, MD 20892.
P C
PC
Adamson
S
S
Zimm
A H
AH
Ragab
S M
SM
Steinberg
F
F
Balis
B A
BA
Kamen
T J
TJ
Vietti
A
A
Gillespie
D G
DG
Poplack
D000293:Adolescent; D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous / Q000379:methods; D008099:Liver / Q000187:drug effects; D015122:Mercaptopurine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D015122:Mercaptopurine